CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–15. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R. Kshitiz: systems biology of cancer metastasis. Cell Syst. 2019;9(2):109–127. doi:10.1016/j.cels.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Riggi N, Aguet M, Stamenkovic I. Cancer metastasis: a reappraisal of its underlying mechanisms and their relevance to treatment. Annu Rev Pathol. 2018;13(1):117–140. doi:10.1146/annurev-pathol-020117-044127.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27(1):34–44. doi:10.1038/s41591-020-01195-4.
   PubMed Web of Science ®Google Scholar
• Chensue SW, Warmington KS, Ruth JH, Sanghi PS, Lincoln P, Kunkel SL. Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. J Immunol. 1996;157:4602–4608.
   PubMed Web of Science ®Google Scholar
• Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:1–9. doi:10.1155/2012/647684.
   Google Scholar
• Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin M-E, Van Den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. Am J Roentgenol. 2011;196(1):117–122. doi:10.2214/AJR.10.5036.
   PubMed Web of Science ®Google Scholar
• Flanagan M, Solon J, Chang KH, Deady S, Moran B, Cahill R, Shields C, Mulsow J. Peritoneal metastases from extra-abdominal cancer - A population-based study. Eur J Surg Oncol. 2018;44(11):1811–1817. doi:10.1016/j.ejso.2018.07.049.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. doi:10.1016/j.immuni.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2020;395(10240):1835–1844. doi:10.1016/S0140-6736(20)30934-X.
   PubMed Web of Science ®Google Scholar
• Hamid O, Molinero L, Bolen CR, Sosman JA, Muñoz-Couselo E, Kluger HM, McDermott DF, Powderly JD, Sarkar I, Ballinger M, et al. Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a phase I trial of atezolizumab. Clin Cancer Res. 2019;25(20):6061–6072. doi:10.1158/1078-0432.CCR-18-3488.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al. Combined nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730. doi:10.1056/NEJMoa1805453.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11. doi:10.1038/s12276-018-0191-1.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–1492. doi:10.1056/NEJM198512053132327.
   PubMed Web of Science ®Google Scholar
• Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010;107(26):11906–11911. doi:10.1073/pnas.1002569107.
   PubMed Web of Science ®Google Scholar
• Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763–777. doi:10.1016/j.it.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26(1):453–479. doi:10.1146/annurev.immunol.26.021607.090357.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–1164.
   PubMed Web of Science ®Google Scholar
• Drerup JM, Deng Y, Pandeswara SL, Padrón ÁS, Reyes RM, Zhang X, Mendez J, Liu A, Clark CA, Chen W, et al. CD122-selective IL2 complexes reduce immunosuppression, promote treg fragility, and sensitize tumor response to PD-L1 blockade. Cancer Res. 2020;80(22):5063–5075. doi:10.1158/0008-5472.CAN-20-0002.
   PubMed Web of Science ®Google Scholar
• Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, et al. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. J Immunother Cancer. 2021;9(4):e002051. doi:10.1136/jitc-2020-002051.
   PubMed Web of Science ®Google Scholar
• Diab A, Tannir NM, Bentebibel S-E, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 2020;10(8):1158–1173. doi:10.1158/2159-8290.CD-19-1510.
   PubMed Web of Science ®Google Scholar
• Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AV, Kancharla A, Sun X, Deng Y. Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021;10(6):2137–2152. doi:10.1002/cam4.3739.
   PubMed Web of Science ®Google Scholar
• Lyon A, Fallon J, Boyerinas B, Schmitz R, Hance KW, Lan Y, Sabzevari H, Tsang K, Schlom J, Greiner J. Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model. J ImmunoTher Cancer. 2014;2(S3): P101. doi:10.1186/2051-1426-2-S3-P101.
   Google Scholar
• Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964–6974. doi:10.1158/0008-5472.CAN-16-0258.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, Curiel TJ. Sequential intravesical mitomycin plus bacillus calmette–guérin for non–muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Clin Cancer Res. 2015;21(2):303–311. doi:10.1158/1078-0432.CCR-14-1781.
   PubMed Web of Science ®Google Scholar
• Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311(5769):1924–1927. doi:10.1126/science.1122927.
   PubMed Web of Science ®Google Scholar
• Tait Wojno ED, Beamer CA. Isolation and identification of innate lymphoid cells (ILCs) for immunotoxicity testing. Methods Mol Biol. 2018;1803:353–370.
   PubMedGoogle Scholar
• Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176(3):1517–1524. doi:10.4049/jimmunol.176.3.1517.
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869. doi:10.3389/fimmu.2018.01869.
   PubMed Web of Science ®Google Scholar
• Nishikado H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H. NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol. 2011;186(10):5766–5771. doi:10.4049/jimmunol.1100370.
   PubMed Web of Science ®Google Scholar
• Simonetta F, Pradier A, Roosnek E. T-bet and eomesodermin in NK cell development, maturation, and function. Front Immunol. 2016;7:241. doi:10.3389/fimmu.2016.00241.
   PubMed Web of Science ®Google Scholar
• Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood J Am Soc Hematol. 2009;113:5488–5496.
   Google Scholar
• Gasteiger G, Hemmers S, Firth MA, Le Floc’h A, Huse M, Sun JC, Rudensky AY. IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med. 2013;210(6):1167–1178. doi:10.1084/jem.20122462.
   PubMed Web of Science ®Google Scholar
• Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med. 2016;8(367):367ra166–367ra166. doi:10.1126/scitranslmed.aag3187.
   PubMed Web of Science ®Google Scholar
• Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology. 2018;7(11):e1509819. doi:10.1080/2162402X.2018.1509819.
   PubMed Web of Science ®Google Scholar
• Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, et al. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Exp Gerontol. 2018;105:146–154. doi:10.1016/j.exger.2017.12.025.
   PubMed Web of Science ®Google Scholar
• Ji S, Lee J, Lee ES, Kim DH, and Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother. 2021;17(7): 1910–1922. PMID: 33522416
   PubMed Web of Science ®Google Scholar
• Gómez-Cuadrado L, Tracey N, Ma R, Qian B, Brunton VG. Mouse models of metastasis: progress and prospects. Dis Model Mech. 2017;10(9):1061–1074. doi:10.1242/dmm.030403.
   PubMed Web of Science ®Google Scholar
• Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers. 2010;3(1):126–163. doi:10.3390/cancers3010126.
   PubMedGoogle Scholar
• Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980;16(2):142–144. doi:10.1016/0090-4295(80)90067-9.
   PubMed Web of Science ®Google Scholar
• Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, Morag E, Bartfeld D, Lotem M, Peretz T, et al. Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expr Purif. 2004;34(2):183–189. doi:10.1016/j.pep.2003.12.006.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738. doi:10.3390/cancers12030738.
   PubMed Web of Science ®Google Scholar
• Sun J-Y, Zhang D, Wu S, Xu M, Zhou X, Lu X-J, Ji J. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomarker Res. 2020;8(1):1–10. doi:10.1186/s40364-020-00212-5.
   PubMed Web of Science ®Google Scholar
• Ji N, Mukherjee N, Shu Z-J, Reyes RM, Meeks JJ, McConkey DJ, Gelfond JA, Curiel TJ, Svatek RS. γδ T cells support antigen-specific αβ T cell-mediated antitumor responses during BCG treatment for bladder cancer. Cancer Immunol Res. 2021. doi:10.1158/2326-6066.CIR-21-0285.
   Web of Science ®Google Scholar
• Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu Z-J, Ramamurthy C, Dennett R. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J ImmunoTher Cancer. 2021;9(3):e001941. doi:10.1136/jitc-2020-001941.
   PubMed Web of Science ®Google Scholar
• Malaisé M, Rovira J, Renner P, Eggenhofer E, Sabet-Baktach M, Lantow M, Lang SA, Koehl GE, Farkas SA, Loss M, et al. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J Immunol. 2014;192(4):1954–1961. doi:10.4049/jimmunol.1300876.
   PubMed Web of Science ®Google Scholar
• Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, Degli-Esposti MA, Smyth MJ, Tarlinton DM, Nutt SL. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol. 2007;178(8):4764–4770. doi:10.4049/jimmunol.178.8.4764.
   PubMed Web of Science ®Google Scholar
• Zhang J, Marotel M, Fauteux‐Daniel S, Mathieu AL, Viel S, Marçais A, Walzer T. T‐bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1. Eur J Immunol. 2018;48(5):738–750. doi:10.1002/eji.201747299.
   PubMed Web of Science ®Google Scholar
• Goh W, Huntington ND. Regulation of murine natural killer cell development. Front Immunol. 2017;8:130. doi:10.3389/fimmu.2017.00130.
   PubMed Web of Science ®Google Scholar
• Hurwitz M, Cho D, Balar A, Curti B, Siefker-Radtke A, Sznol M, Kluger H, Bernatchez C, Fanton C, Iacucci E, et al. Baseline tumor immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. J Clin Oncol. 2019;37(15_suppl): Abstract 2623. doi:10.1200/JCO.2019.37.15_suppl.2623.
   Web of Science ®Google Scholar